Poolbeg Pharma
BalancedPOLB·XLON·🇬🇧 GB
50%buys·50%sales
0 transactions$0Total buys·0 buys
$0Total sells·0 sells
00 insiders
—Last: —
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Jun 25, 25 | of PDMR | Buy | $13.6M | |
| Feb 21, 24 | of PDMR Jeremy Skillington | Buy | $2.1M | |
| Feb 21, 24 | of PDMR | Buy | $2.1M | |
| Feb 19, 24 | of PDMR Cathal Friel | Buy | $12.2M | |
| Feb 19, 24 | of PDMR | Buy | $12.2M |
companyInsight.narrative_dormancy
Poolbeg Pharma (POLB) has recorded 0 insider operations, including 0 open-market purchases ($0), 0 sales ($0). The insider sentiment is balanced.
Recent activity is concentrated over 1 months in the last year.
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
Poolbeg Pharma has recorded 0 insider operations in total, including 0 open-market purchases ($0), 0 sales ($0).
Insiders at Poolbeg Pharma show balanced activity with 50% purchases and 50% sales. Total buy volume is $0 versus $0 in sales.
InsiderLens tracks 0 insiders at Poolbeg Pharma (POLB). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for POLB is neutral, based on a 50% buy ratio across 0 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for Poolbeg Pharma comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.